BG-75202 features among several projects starting first-in-human trials.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
Roche dumps another partnered asset.
PD-(L)1 x VEGF developments coinciding with ASCO overshadowed the conference proper.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Meanwhile, Ichnos Glenmark takes a different trispecific multiple myeloma approach.
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
